Announcement • May 24

Legend Biotech Corporation to Highlight Leadership in CAR-T Cell Therapy for Patients with Multiple Myeloma at ASCO and EHA

Legend Biotech Corporation announced that new and updated data from the CARTITUDE clinical development program evaluating CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) for patients with multiple myeloma will be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting and the 2024 European Hematology Association’s (EHA) Hybrid Congress. Data from Cohort D of the Phase 2 CARTITUDE-2 study investigating a single infusion of CARVYKTI® with or without lenalidomide maintenance in patients who achieved less than complete response after autologous stem cell transplant (ASCT) frontline therapy will be presented for the first time in an oral presentation at ASCO and in an encore oral presentation at EHA. Data from the subgroup analysis of the Phase 3 CARTITUDE-4 study of CARVYKTI® versus two standard therapies in patients with functional high-risk multiple myeloma after one prior line of treatment will be presented in an oral presentation at ASCO. Additionally, the results of the CARTITUDE-4 subgroup analysis by cytogenetic risk will be shared at EHA in a poster session. INCREASED EARLY MORTALITY - In CARTITUDE-4, a (1:1) randomized controlled trial, there was a numerically higher percentage of early deaths in patients randomized to the CARVYKTI® treatment arm compared to the control arm. Among patients with deaths occurring within the first 10 months from randomization, a greater proportion (29/208; 14%) occurred in the CARVYKTI® arm compared to (25/211; 12%) in the control arm. Of the 29 deaths that occurred in the CARVYKTI® arm within the first 10 months of randomization, 10 deaths occurred prior to CARVYKTI® infusion, and 19 deaths occurred after CARVYKTI® infusion. Of the 10 deaths that occurred prior to CARVYKTI® infusion, all occurred due to disease progression, and none occurred due to adverse events. Of the 19 deaths that occurred after CARVYKTI® infusion, 3 occurred due to disease progression, and 16 occurred due to adverse events. The most common adverse events were due to infection (n=12). CYTOKINE RELEASE SYNDROME (CRS),including fatal or life-threatening reactions, occurred following treatment with CARVYKTI®. Among patients receiving CARVYKTI® for RRMM in the CARTITUDE-1 & 4 studies (N=285), CRS occurred in 84% (238/285), including = Grade 3 CRS (ASCT 2019) in 4% (11/285) of patients. Median time to onset of CRS, any grade, was 7 days (range: 1 to 23 days). CRS resolved in 82% with a median duration of 4 days (range: 1 to 97 days). The most common manifestations of CRS in all patients combined (= 10%) included fever (84%), hypotension (29%) and aspartate aminotransferase increased (11%). Serious events that may be associated with CRS include pyrexia, hemophagocytic lymphohistiocytosis, respiratory failure, disseminated intravascular coagulation, capillary leak syndrome, and supraventricular and ventricular tachycardia. CRS occurred in 78% of patients in CARTITUDE-4 (3% Grade 3 to 4) and in 95% of patients in CARTITUDE-1 (4% Grade 3 to 4). Identify CRS based on clinical presentation. Evaluate for and treat other causes of fever, hypoxia, and hypotension. CRS has been reported to be associated with findings of HLH/MAS, and the physiology of the syndromes may overlap. HLH/MAS is a potentially life-threatening condition. In patients with progressive symptoms of CRS or refractory CRS despite treatment, evaluate for evidence of HLH/MAS. Please see Section 5.4; Hemophagocytic Lymphohistiocytosis (HLH)/Macrophage Activation Syndrome (MAS) Ensure that a minimum of two doses of tocilizumab are available prior to infusion of CARVYKTI®. Of the 285 patients who received CARVYKTI® in clinical trials, 53% (150/285) patients received tocilizumab; 35% (100/285) received a single dose, while 18% (50/285) received more than 1 dose of tocilizumab. Overall, 14% (39/285) of patients received at least one dose of corticosteroids for treatment of CRS. Monitor patients at least daily for 10 days following CARVYKTI® infusion at a REMS-certified healthcare facility for signs and symptoms of CRS. Monitor patients for signs or symptoms of CRS for at least 4 weeks after infusion. At the first sign of CRS, immediately institute treatment with supportive care, tocilizumab, or tocilizumab and corticosteroids. Counsel patients to seek immediate medical attention should signs or symptoms of CRS occur at any time. NEUROLOGIC TOXICITIES, which may be severe, life-threatening, or fatal, occurred following treatment with CARVYKTI®. Neurologic toxicities included ICANS, neurologic toxicity with signs and symptoms of parkinsonism, GBS, immune mediated myelitis, peripheral neuropathies, and cranial nerve palsies. Counsel patients on the signs and symptoms of these neurologic toxicities, and on the delayed nature of onset of some of these toxicities. Instruct patients to seek immediate medical attention for further assessment and management if signs or symptoms of any of these neurologic toxicities occur at any time. Among patients receiving CARVYKTI® in the CARTITUDE-1 & 4 studies for RRMM, one or more neurologic toxicities occurred in 24% (69/285), including = Grade 3 cases in 7% (19/285) of patients. Median time to onset was 10 days (range: 1 to 101) with 63/69 (91%) of cases developing by 30 days. Neurologic toxicities resolved in 72% (50/69) of patients with a median duration to resolution of 23 days (range: 1 to 544). Of patients developing neurotoxicity, 96% (66/69) also developed CRS. Subtypes of neurologic toxicities included ICANS in 13%, peripheral neuropathy in 7%, cranial nerve palsy in 7%, parkinsonism in 3%, and immune mediated myelitis in 0.4% of the patients. Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS): Patients receiving CARVYKTI® may experience fatal or life-threatening ICANS following treatment with CARVYKTI®, including before CRS onset, concurrently with CRS, after CRS resolution, or in the absence of CRS. Among patients receiving CARVYKTI® in the CARTITUDE-1 & 4 studies, ICANS occurred in 13% (36/285), including Grade =3 in 2% (6/285) of the patients. Median time to onset of ICANS was 8 days (range: 1 to 28 days). ICANS resolved in 30 of 36 (83%) of patients with a median time to resolution of 3 days (range: 1 to 143 days). Median duration of ICANS was 6 days (range: 1 to 1229 days) in all patients including those with ongoing neurologic events at the time of death or data cut-off. Of patients with ICANS, 97% (35/36) had CRS. The onset of ICANS occurred during CRS in 69% of patients, before and after the onset of CRS in 14% of patients respectively. Immune Effector Cell-associated Neurotoxicity Syndrome (ICANS) occurred in 7% of patients in CARTITUDE-4 (0.5% Grade 3) and in 23% of patients in CARTITUDE-1 (3% Grade 3). The most frequent =2% manifestations of ICANS included encephalopathy (12%), aphasia (4%), headache (3%), motor dysfunction (3%), ataxia (2%), and sleep disorder (2%) [see Adverse Reactions (6.1)].

CEO salary percentage	n/a
CEO tenure	no data
CEO ownership	n/a
Management average tenure	less than a year
Board average tenure	3.9yrs

Name	Position	Tenure	Compensation	Ownership
Alan Bash	Interim CEO & President of CARVYKTI Business Unit	no data	no data	no data
Carlos Santos	Chief Financial Officer	less than a year	no data	no data
Jessie Yeung	Vice President of Finance	less than a year	no data	no data
James Pepin	General Counsel	2.7yrs	no data	no data
Ananda Martin	Global Compliance Officer	less than a year	no data	no data
Ying Huang	Advisor	no data	no data	0.062% € 2.0m
Guowei Fang	President of Research & Development	no data	no data	no data
Birk Vanderweeen	Senior Vice President of Global Manufacturing & Supply	2.7yrs	no data	no data
Surabhi Verma	Manager of Investor Relations & Corporate Communications	no data	no data	no data
Joanne Choi	Senior Manager of Investor Relations	no data	no data	no data

Name	Position	Tenure	Compensation	Ownership
John Michael Maraganore	Member of Strategic Advisory Board	3.3yrs	no data	no data
Corazon Sanders	Independent Director	6.2yrs	no data	0.010% € 334.0k
Gareth Kung	Independent Director	less than a year	no data	no data
Xiaohui Ji	Independent Director	6.2yrs	no data	0.010% € 319.1k
Tomas Heyman	Independent Director	3.9yrs	no data	0.0037% € 116.9k
Fangliang Zhang	Independent Chairman	3.9yrs	no data	no data
Ye Wang	Director	11.2yrs	no data	0% € 0
Jiange Meng	Director	less than a year	no data	no data
Michel Vounatsos	Member of Strategic Advisory Board	3.3yrs	no data	no data
Patrick Casey	Independent Director	5.6yrs	no data	0.0092% € 294.6k
Li Mao	Independent Director	3.9yrs	no data	0.0067% € 212.4k
Peter Salovey	Lead Independent Director	1.9yrs	no data	0.0014% € 43.0k

Data	Last Updated (UTC time)
Company Analysis	2026/07/30 10:57
End of Day Share Price	2026/07/29 00:00
Earnings	2026/03/31
Annual Earnings	2025/12/31

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

Analyst	Institution
Etzer Darout	Barclays
Huidong Wang	Barclays
Rick Bienkowski	Cantor Fitzgerald & Co.

Legend Biotech Management

Management criteria checks 1/4

Key information

Recent management updates

Legend Biotech Corporation Announces That Ying Huang, Ph.D., Has Stepped Down as A Member of the Board of Directors, Effective as of July 24, 2026

Legend Biotech Corporation Announces Board and Audit Committee Changes, Effective February 2, 2026

Legend Biotech Corporation Announces Changes to Board of Directors and Audit Committee, Effective January 20, 2026

Legend Biotech Corporation Announces Chief Financial Officer Changes

Legend Biotech Corporation Appoints Peter Salovey as Lead Independent Director, Effective June 5, 2025

Legend Biotech Corporation Appoints Alan Bash as President of CARVYKTI®

Recent updates

Legend Biotech Corporation to Report Q2, 2026 Results on Aug 11, 2026

Legend Biotech Corporation Announces That Ying Huang, Ph.D., Has Stepped Down as A Member of the Board of Directors, Effective as of July 24, 2026

Legend Biotech Corporation has completed a Follow-on Equity Offering in the amount of $225.995 million.

Legend Biotech Establishes Clinical Proof-of-Concept for LB2501 in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

New major risk - Share price stability

Legend Biotech Corporation Announces Late-Breaking Oral Presentation of Initial Phase 1 in Vivo Car-T Data with Lb2501 in Non-Hodgkin Lymphoma

Legend Biotech Corporation Announces Board and Audit Committee Changes, Effective February 2, 2026

Legend Biotech Corporation Announces Changes to Board of Directors and Audit Committee, Effective January 20, 2026

Legend Biotech Corporation Announces U.S. Fda Approves Label Updates for Carvykti® Car-T Cell Therapy to Include Overall Survival Data

Legend Biotech Corporation Announces Chief Financial Officer Changes

Legend Biotech Corporation to Report Q2, 2025 Results on Aug 11, 2025

Legend Biotech Corporation Appoints Peter Salovey as Lead Independent Director, Effective June 5, 2025

Legend Biotech Corporation Unveils 5-Year Survival Data for Carvykti®? in Multiple Myeloma At 2025 Asco Annual Meeting

Legend Biotech Corporation to Present New Data on Carvykti for Patients with Multiple Myeloma At 2025 Asco and Eha Annual Meeting

Legend Biotech Corporation Announces New Results from the Phase 3 CARTITUDE-4 Study

Third quarter 2024 earnings released: US$0.68 loss per share (vs US$0.34 loss in 3Q 2023)

Legend Biotech Corporation Appoints Alan Bash as President of CARVYKTI®

New minor risk - Share price stability

Legend Biotech Corporation, Annual General Meeting, Oct 21, 2024

Legend Biotech Achieves Breakthrough with Cilta-Cel Approval in China, Offering New Hope for Multiple Myeloma Patients

Second quarter 2024 earnings released: US$0.10 loss per share (vs US$1.14 loss in 2Q 2023)

Legend Biotech Corporation Appoints Peter Salovey as Independent Director, Effective August 9, 2024

Legend Biotech Corporation Announces Positive Overall Survival Results of Phase 3 CARTITUDE-4 Trial in Multiple Myeloma

Legend Biotech Corporation Shares Data on the Earlier Use to Date of CARVYKTI in the Treatment of Multiple Myeloma and Important Subgroup Analyses At ASCO and EHA

Legend Biotech Corporation to Highlight Leadership in CAR-T Cell Therapy for Patients with Multiple Myeloma at ASCO and EHA

First quarter 2024 earnings released: US$0.32 loss per share (vs US$0.68 loss in 1Q 2023)

Legend Biotech Corporation's CARVYKTI® (ciltacabtagene autoleucel) Approved by the European Commission for Second-line Treatment of Patients with Relapsed and Refractory Multiple Myeloma

Legend Biotech Corporation Announces CARVYKTI (Ciltacabtagene Autoleucel) Receives Recommendation from the U.S. FDA Oncologic Drugs Advisory Committee for Earlier Treatment of Patients with Relapsed/Refractory Multiple Myeloma

Full year 2023 earnings released: US$2.94 loss per share (vs US$2.81 loss in FY 2022)

Legend Biotech Provides Update on U.S. FDA and EMA Applications for Expanded Use of CARVYKTI® (ciltacabtagene autoleucel) in Earlier Lines of Treatment for Relapsed/Refractory Multiple Myeloma

Legend Biotech Announces U.S. FDA Label Update for CARVYKTI® (ciltacabtagene autoleucel; cilta-cel)

Legend Biotech Corporation Announces Patient-Reported Outcome (Pro) Data from the Phase 3 CARTITUDE-4 Study

Third quarter 2023 earnings released: US$0.34 loss per share (vs US$0.68 loss in 3Q 2022)

Legend Biotech Corporation, Annual General Meeting, Sep 21, 2023

Second quarter 2023 earnings released: US$1.14 loss per share (vs US$1.25 loss in 2Q 2022)

Legend Biotech Corporation Announces Submission of Supplemental Application to U.S. FDA for Expanded Use of CARVYKTI® (Ciltacabtagene Autoleucel)

Legend Biotech Corporation Announces Results from the Phase 3 CARTITUDE-4 Study

Legend Biotech Corporation Announces Submission to the European Medicines Agency for Expanded Use of CARVYKTI®? (Ciltacabtagene Autoleucel)

First quarter 2023 earnings released: US$0.68 loss per share (vs US$0.27 loss in 1Q 2022)

Legend Biotech Corporation to Demonstrate Progress in Advancing Potential Treatment Options for Patients with Multiple Myeloma at ASCO and EHA Annual Meetings

Legend Biotech Corporation has completed a Follow-on Equity Offering in the amount of $350 million.

Full year 2022 earnings released

Second quarter 2022 earnings released: US$1.25 loss per share (vs US$0.66 loss in 2Q 2021)

Legend Biotech Corporation Announces Research and Development Update

Legend Biotech Receives Notification of Delinquency from The Nasdaq Stock Market LLC

Legend Biotech Announces Acceptance of Its New Drug Application for Ciltacabtagene Autoleucel (Cilta-Cel) in China

Legend Biotech Corporation Announces FDA Clearance of IND Application for LB2102 in Extensive Stage Small Cell Lung Cancer

High number of new and inexperienced directors

Legend Biotech Corporation Shares Updated Data from Comprehensive Cilta-Cel Clinical Development Program at ASH 2022

Legend Biotech Corporation Elects Philip Yau as Director

Legend Biotech Corporation Announces that CARVYKTI™ (ciltacabtagene autoleucel) Receives Approval from Japan’s Ministry of Health, Labour and Welfare (MHLW) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma

Legend Biotech Corporation, Annual General Meeting, Oct 14, 2022

Legend Biotech Corporation Provides Earnings Guidance for the Six Months Ended June 30, 2022

Legend Biotech Corporation Announces Board Changes

Legend Biotech Corporation has completed a Follow-on Equity Offering in the amount of $350.02 million.

First quarter 2022 earnings released: US$0.27 loss per share (vs US$0.61 loss in 1Q 2021)

Legend Biotech Corporation Legend Biotech Announces Termination of Its Phase 1 Clinical Trial Under Investigational New Drug Application for LB1901

Longer-Term Data from CARTITUDE Program Continue to Show Deep and Durable Responses with Ciltacabtagene Autoleucel Across Lines of Therapy in Patients with Multiple Myeloma

Legend Biotech Corporation Announces U.S. FDA Clearance of IND Application for Solid Tumor Car-T, Lb1908 for Relapsed or Refractory Gastric, Esophageal and Pancreatic Cancers

First quarter 2022 earnings released: US$0.27 loss per share (vs US$0.61 loss in 1Q 2021)

European Commission Grants Marketing Authorization to CARVYKTI of Legend Biotech Corporation

Legend Biotech Appoints Lori Macomber as Chief Financial Officer

High number of new and inexperienced directors

Legend Biotech Announces Executive Changes

Legend Biotech Corporation Announces Appointment of Guowei Fang as Global Head of Research and Early Development

Full year 2021 earnings released: US$2.74 loss per share (vs US$2.57 loss in FY 2020)

Legend Biotech Corporation's CARVYKTI™ (ciltacabtagene autoleucel), BCMA-Directed CAR-T Therapy, Receives U.S. FDA Approval for the Treatment of Adult Patients With Relapsed or Refractory Multiple Myeloma

Legend Biotech Announces FDA Clinical Hold of Its Phase 1 Clinical Trial for LB1901

Forecast to breakeven in 2024